| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2002;22:957-964
© 2002 Elsevier Science NL
a Department of Cardiovascular Surgery, Albert-Ludwigs-University Freiburg, Freiburg, Germany
b Department of Surgical Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany
Received 5 May 2002; received in revised form 2 September 2002; accepted 4 September 2002.
* Corresponding author. Tel.: +49-761-270-2818; fax: +49-761-270-2550
e-mail: lutter{at}ch11.ukl.uni-freiburg.de
 |
Abstract |
|---|
 Top Abstract 1. Introduction2. Material and methods3. Results4. DiscussionReferences |
|---|
Key Words: Coronary disease • Fibroblast growth factor-2 • Gene expression • Angiogenesis • Perfusion • Contractility
|
1. Introduction |
|---|
|
TopAbstract1. Introduction2. Material and methods3. Results4. DiscussionReferences |
|---|
Intramyocardial injection of agents strictly targets the area in need. Protein application is characterized by a defined dose but limited tissue half-life, whereas gene injection results in poorly predictable amount of protein production but prolonged presence of the growth factor. Results of clinical trials with intramyocardial delivery of a VEGF165 DNA plasmid [5] or, as in our previous study, of free recombinant FGF-1 [6,7] suggest, that both applications can be successfully employed for treatment of chronic myocardial ischemia.
The objective of our present study was to compare the effectiveness of intramyocardial injection of protein compared to naked plasmid DNA for FGF-2 with regard to vessel growth (angiogenesis and arteriogenesis), perfusion, and cardiac function in a porcine model of chronically myocardial ischemia.
|
2. Material and methods |
|---|
|
TopAbstract1. Introduction2. Material and methods3. Results4. DiscussionReferences |
|---|
2.2. Animals and anaesthesia
All animal procedures were performed in compliance with the ‘Principles of Laboratory Animal Care‘, the ‘Guide for the Care and Use of Laboratory Animals‘, National Institute of Health publication 85-23, revised 1985, and the German ‘Law for Animal Protection’. Pigs of ‘German Landrace‘ weighting 24–30 kg were premedicated, anaesthetized, and monitored as previously described [8]. Sufficient analgesics as well as acetyl salicylic acid and antibiotics were given after the first and second operation.
To mimic clinical coronary artery disease, we employed a model of chronic myocardial ischemia [9]. In the first operation, an operative stenosis of the left anterior descending artery (LAD) was created in the ischemic experimental groups. One week later (second operation), the animals were studied by analyzing different parameters (see Section 2.3). Afterwards, pigs were designated to one of three different experimental groups. After 12 weeks (third operation), the animals were re-examined (same parameters as before) and sacrificed. One additional pig received the EGFP plasmid and was sacrificed 2 days later.
2.2.1. First operation
The heart was exposed via an anterolateral minithoracotomy. The LAD was carefully dissected and isolated immediately distal to the bifurcation of the first diagonal branch (D1) over 1–2 cm to accept an ultrasonic transit time (UTT) flow probe (Transonic Systems, Inc, Ithaca, NY) recording downstream flow through the LAD. A severe LAD stenosis (immediately distal to D1) was created proximal to the flow probe by the arterial puncture needle technique [9] to produce an area at risk of about 25% of the LV anterior free wall.
The blood flow distal of the stenosis was reduced to about 50% as assessed by UTT and coronarography. The wound was closed in layers, and the animals were allowed to recover.
2.2.2. Second operation
Through a re-minithoracotomy, the pericardium was opened and the heart was reexposed 7 days after the onset of chronic ischemia under the same conditions as described above. The monitoring was performed, as reported elsewhere [10].
Once angiography and UTT flow probe data confirmed the presence of chronic ischemia (severe LAD stenosis with blood flow reduction, see above); baseline measurements of segmental myocardial shortening, left ventricular stroke work index, and time derivative of maximal left ventricular pressure were assessed as described below at rest and under stress. Stress was exerted by intravenous application of dobutamine in increasing doses up to 20 µg/min per kg. In addition, fluorescent microspheres were injected for examination of regional perfusion as described below. Animals were designated to one of three groups. To define this area at risk the LAD was occluded for 10 s prior to treatment. The pigs received therapy or were left untreated (see Section 2.2.3). The thorax was closed, and the pigs were allowed to recover.
2.2.3. Experimental groups
Pigs received 500 µg human recombinant Fibroblast growth factor-2 (Pepro Tech Inc., Rocky Hill, NJ) [recFGF-2, n=6]) or 2 mg FGF-2 plasmid [plasFGF-2, n=7]. Both agents were supplemented with 400 IE Heparin and diluted in 0.9% sodium chloride to a total volume of 2.8 ml. Out of this amount, 15 aliquots were injected equidistantly into the myocardium across the ischemic area. The third group did not receive injections and was left untreated [ischemia, n=7].
2.2.4. Third operation
After 3 months, a sternotomy was performed. The animals were reassessed similarly to the second operation and sacrificed. The hearts were removed and cut in 5 mm transversal sections. Samples were taken from the ischemic area as well as from the posterior wall and fixed in paraformaldehyde.
2.3. Parameters
2.3.1. Enhanced green fluorescent protein
Myocardial samples were put into 0.1 M potassium phosphate buffer ph 7.6 containing 15% saccharose and preserved at -20 °C. The nuclei were counterstained using propidium iodide (0.5 µg/ml) in cryosections, and fluorescence was observed using a fluorescence microscope (Zeiss, Germany).
2.3.2. Vessel counting
Myocardial sections were fixed in 4% formaldehyde in phosphate buffer immediately after removal and embedded in paraffinum. Sections were taken from the ischemic area or, for control purposes, from the corresponding myocardium of healthy untreated weight-matched pigs (n=5). Slices were pretreated with methanol, H2O2, and pepsin (Sigma, Taufkirchen, Germany), and double-stained after blocking with the appropriate serum. Endothelial cells were identified by successive incubation with anti-Von Willebrand Factor (DAKO, Hamburg, Germany), biotinylated swine anti-rabbit F(ab')2 fragment (DAKO), Streptavidin-biotinylated alkaline phosphatase-complex (DAKO), and Fast Blue (Sigma). For staining of smooth muscle cells, anti-Smooth muscle actin (DAKO), biotinylated rabbit anti-mouse F(ab')2 fragment (DAKO), and Streptavidin-biotinylated Horseradish Peroxidase-complex (DAKO) were used followed by development with DAB (Sigma). Counting of capillaries (400-fold enlargement) and arterioles (200-fold enlargement) was performed by trained observers blinded to the experimental conditions. Arterial structures with more than three layers of smooth muscle cells were considered arteries and were excluded. For each animal, 40 visual fields from different sections were counted.
2.3.3. Regional myocardial blood flow (RMBF)
Regional perfusion of the territories of the LAD and left circumflex artery was measured by fluorescent microspheres (Molecular Probes, Eugene, OR) based on the arterial reference sample technique [8,11]. The microsphere suspensions (15±0.1 µm; density of 1.07 g/ml) were injected into the left atrium under stable hemodynamic conditions. The reference samples were withdrawn from the internal carotid artery over a 2 min period at a rate of 10 ml/min starting 5 s before the injection of microspheres. Microspheres were injected at rest and under stress in all animals at the second (before application of therapy) and third operation (Harvard apparatus, South Natick, MA). Different colours were used for the four study points in each animal.
At the end of study, myocardial samples were taken from the ischemic area. The microspheres were retrieved from the tissue according to the manufacturers’ instructions and the resulting fluorescence was measured.
2.3.4. Segmental myocardial shortening (SMS)
Assessment of segmental myocardial shortening (SMS) was performed at rest and under stress in all animals using ultrasonic crystals (Transonic Systems, Inc., Ithaca, NY), as previously described [8].
SMS was calculated as follows:
 |
SMS were analyzed at three different times: before stenosis (first operation), after 1 week chronic ischemia (second operation, baseline), and after 3 months ischemia (third operation).
2.3.5. Hemodynamic measurements
Hemyodynamic measurements of LV pressure, maximum of the first derivative of left ventricular pressure at a defined left atrial pressure (dp/dtmax) measured by Millar catheter (Millar, Houston, TX), and maximal left ventricular stroke work index (LVSWImax) were monitored continuously and recorded at rest and under stress in all experimental groups. Stress was induced by IV application of dobutamine for 10 min at a dose of 10 µgxkg-1xmin-1, followed by a dose of 20 µgxkg-1xmin-1 IV for another 10 min. Left ventricular stroke work was normalized for heart frequency (HF) and body weight (BW) and calculated as:
 |
The maximal-achieved LVSWI (LVSWImax) was used for comparison between the experimental groups.
All parameters were assessed after 1 week (second operation, baseline) and three months of chronic ischemia (third operation) at rest and under stress conditions.
2.3.6. Statistical analysis
Data were analyzed based upon Wilcoxon's signed rank test to compare paired data, and Mann–Whitney U-test to compare unpaired data for non-normally distributed data, as appropriate (SPSS-vers. 10.01). Results are expressed as mean±standard deviation (SD). A P-value less than 0.05 was considered statistically significant. Only data were used from animals who survived the entire 13-week observation period and suffered no apparent infarction.
|
3. Results |
|---|
|
TopAbstract1. Introduction2. Material and methods3. Results4. DiscussionReferences |
|---|
|
|
|
3.3. Regional myocardial blood flow (RMBF)
Regional perfusion in the ischemic area was assessed using fluorescent microspheres employing the arterial reference sample technique after 1 week of ischemia before the application of growth factors (baseline), and three months later. The analysis of the ischemic LAD area indicated better regional blood flow at rest following the injection of plasFGF-2 (P=0.043 versus baseline), whereas no treatment or recFGF-2 did not render improvement (P=0.735 and P=0.068 versus baseline, respectively). However, there were no significant changes observed under stress conditions (ischemia: P=0.917, recFGF-2: P=0.6, plasFGF-2: P=0.463 versus baseline) (Table 1).
|
|
|
3.5. Maximal left ventricular stroke work index (LVSWImax)
After 3 months, there was a decline of the LVSWImax (Table 2) at rest in the ischemic and recFGF-2 groups (ischemia, P=0.018, recFGF-2, P=0.028 versus baseline), which was not observed in the plasFGF-2 group (P=0.091 versus baseline). PlasFGF-2 therapy achieved higher LVSWImax values compared to recFGF-2 at rest (P=0.032). However, the groups receiving therapy did not differ from the untreated ischemic control after 3 months (recFGF-2, P=0.668, plasFGF-2, P=0.565).
|
3.5.1. Maximum of the first derivative of left ventricular pressure (dp/dtmax)
Therapy with plasFGF-2 injection resulted in higher dp/dtmax values at rest compared to the untreated control (P=0.012), whereas recFGF-2 therapy did not show this effect (P=0.15 versus ischemia). The treatment groups did not differ from one another (P=0.391).
There was no improvement of dp/dtmax in comparison with the ischemic group under stress conditions (recFGF-2, P=0.317, plasFGF-2, P=0.182) (Table 2).
|
4. Discussion |
|---|
|
TopAbstract1. Introduction2. Material and methods3. Results4. DiscussionReferences |
|---|
One week after creation of a severe LAD stenosis, the agents were injected intramyocardially across the ischemic area. Plasmid-driven protein synthesis could be proven after 2 days. Control animals were left untreated. The results were evaluated 3 months later.
The process of collateralization involves angiogenesis, which is the sprouting of new capillaries, and arteriogenesis, the development of arterial structures from small preexisting collateral vessels [12]. Arteriogenesis is considered to be more important than angiogenesis due to higher perfusion capacity of arterial vessels. In our model, untreated ischemia resulted in a significant reduction of capillaries, but not of arterioles. FGF-2 protein injections as well as plasmid injections caused an increase in the number of capillaries and arterioles compared to untreated ischemia.
Furthermore, after FGF-2 plasmid treatment a significantly higher number of arterioles were present even compared to normal myocardium. The reasons for this phenomenon are so far not clear. We did not observe related adverse effects in our study. A limitation of our assessment is that we only counted the vessels and did not measure their diameter. Therefore, the additional restructuring of small arterioles to larger vessels could have eluded our observations.
The results of our study are somewhat incongruous concerning regional myocardial blood flow and segmental myocardial shortening. Whereas regional contractility benefits from FGF-2 plasmid therapy at rest and under stress, a better perfusion of the ischemic area is observed only at rest. The improvement corresponds to the increase in the number of arterioles, which is strongest with gene therapy. However, the mere number of arteriolar structures does not reflect vessel quality. Therefore, the proper physiological response of newly-built vessels to stress cannot be predicted. This might explain the lack of flow reserve. The improvement of regional contractility, that was observed nevertheless, could be due to protective effects of FGF-2 on cardiomyocytes previously shown in vivo [13,14].
Systemic hemodynamics were examined by left ventricular stroke work index and dp/dtmax at rest and under stress conditions. There were improvements at some points following plasFGF-2 treatment, however, this was not a striking overall-picture.
In the present study, angiogenesis and arteriogenesis were achieved by application of both FGF-2 protein and plasmid. Opinions differ as to whether angiogenesis can be caused by a mere needle puncture of the myocardium. Whereas Chu et al. [15] demonstrate angiogenesis, Horvath et al. [16] do not observe this effect. Both experiments were done in porcine models of myocardial ischemia in context with transmyocardial laser revascularization. In a clinical study, Pecher et al. [7] injected intramyocardially FGF-1 or, for control purposes, the heat denatured factor. The results proved the superiority of the active protein.
Our results are in line with previously reported effects of FGF-2 treatment. Following intramyocardial application in a porcine infarction model [17], arteriogenesis, but not angiogenesis were observed in the border zone of the infaction and even in normal myocardium. FGF-2 has also been employed recently in double-blind randomized clinical studies. Coronary ischemic disease was the subject of the FGF Initiating RevaScularization Trial, wherein a single intracoranary infusion of recombinant FGF-2 achieved symptomatic improvement after three but not after 6 months but did not improve perfusion or exercise tolerance [18]. In contrast, intramyocardial injection of FGF-1 in combination with coronary artery bypass grafting rendered angiogenesis and an increase in the left ventricular ejection fraction [7]. In patients with peripheral arterial disease, intraarterial FGF-2 increased the calf blood flow [19].
However, it is difficult to compare results from different experimental and clinical settings, because ischemia, infarction, or even adding a surgical procedure, e.g. a coronary artery bypass grafting, provide different environments which could alter the influence of the growth factor.
In addition, one might speculate that different agents require different applications to function optimally. For instance, a protein might work best when delivered intracoronarally or intrapericardially, whereas gene therapy achieves better results when injected intramyocardially. The most effective application method might even differ for different growth factors depending on their cellular target, e.g. vascular endothelial cells or stromal cells.
Exogeneously delivered proteins are quickly eliminated in tissues and serum. Following intramyocardial injection of FGF-2, 5% of the injectate is retained for up to 3 days [20]. In contrast, gene expression from naked plasmid DNA under control of the CMV promotor was observed in cardiomyocytes for 8 days peaking on the first day after intramyocardial injection [21].
Although animal studies indicate that gene therapy employing single growth factors is able to promote unwanted vessel growth or atherosclerosis under certain conditions, a number of recent clinical trials have lead to the conclusion that gene therapy is a safe procedure implying a low risk of mortality. Additionally, no development of vascular malformations, neoplasms, atherosclerosis, or retinopathy was to be found in these human studies [22].
However, to avoid these potential problems – and to stimulate an effective collateralization more physiologically – several approaches of a multifactor-therapy are currently under investigation: combination of growth factors, injection of transcription factors like HIF, which control a series of genes, or application of stem/progenitor cells, which synthetize a set of factors.
In our experimental setting, FGF-2 plasmid application rendered better results than protein with regard to perfusion as well as regional contractility and systemic hemodynamics. They indicate, that FGF-2 plasmid therapy might be a more suitable tool for treatment of chronic myocardial ischemia than protein application.
|
References |
|---|
|
TopAbstract1. Introduction2. Material and methods3. Results4. DiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  C. Heilmann and F. Beyersdorf Editorial comment Growth factor therapy grows, despite limited insight. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 107 - 108. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Morishita, M. Aoki, and T. Ogihara Does gene therapy become pharmacotherapy? Exp Physiol, May 1, 2005; 90(3): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A.U. Heilmann, T. Attmann, A. Thiem, E. Haffner, F. Beyersdorf, and G. Lutter Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 785 - 793. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
